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Summary 
The major histocompatibility complex (MHC) class I molecules expressed at the cell surface 
are associated with a large number of different peptides so that the density of a given MHC-pep- 
tide complex is relatively low. Here we describe the properties of MHC class I molecules geneti- 
cally attached to a single antigenic peptide. Cells expressing these fusion proteins are recognized 
by T cells specific for the particular MHC-peptide complex. Coculture of naive splenocytes with 
cells expressing these MHC-peptide fusion proteins and the B7.1 antigen allows the induction 
of primary cytotoxic T lymphocytes (CTL) in vitro. Injection of these cells into naive mice en- 
hances the frequency of specific CTL precursors and protects against a subsequent challenge with 
a tumor or a virus bearing the antigenic peptide. Soluble MHC-peptide fusions were also pro- 
duced in which all three components, that is, the heavy chain, B2-microglobulin and the pep- 
tide, have fused into a single-chain protein. The availability  of MHC class I molecules bound 
to a single peptide provides valuable tools for the manipulation of CTL responses and the analysis 
of the selection processes  in the thymus. 
T 
he MHC class I molecules present peptides which are 
mainly derived from endogenously synthesized proteins 
(1, 2). These MHC-peptide complexes can be recognized by 
T  cells bearing specific TCRs  (for review see reference 3). 
A  given cell expresses  10s-106 MHC class I molecules (4) 
and probably presents up to  104 different peptides or per- 
haps even more (5). A specific MHC-peptide complex is there- 
fore present in small amounts per cell.  100-200 complexes 
are sufficient to sensitize a target cell for lysis by an already 
activated CTL clone (6). This number, however, is too low 
to activate CTL precursors from a naive mouse. 
CTL have often proven to be both efficient and specific 
against viruses. Eliciting CTL against tumors has also been 
a major goal of immunologists. Since tumors are variants of 
normal cells, most peptides presented by a tumor cell are self- 
peptides. Self-specific CTL are normally deleted in the thymus 
through a process called negative selection. The only immuno- 
genic peptides in a tumor are actually often poorly presented, 
either because they are derived from poorly expressed pro- 
teins or because they bind poorly to the MHC molecules. 
Increasing the density of a specific MHC-peptide may help 
induce specific CTL, especially against a tumor, and different 
strategies have been taken. Mutant cell lines deficient in the 
translocation of endogenous peptides into the lumen of the 
endoplasmic reticulum (EtL) 1 can be efficiently loaded with 
exogenous peptides and have been used to induce specific CTL. 
Their use in vivo, however, is limited by allogenic or xeno- 
genic reactivity. 
MHC class I molecules are heterodimers composed of a 
polymorphic transmembrane heavy chain noncovalently as- 
sociated with/32-microglobulin (/32m). We took advantage 
of their known tridimensional structure (7-9)  to produce 
soluble  K a,  K b,  and  HLA-A2  molecules  by  connecting 
through an appropriate peptidic link the COOH  terminus 
of the third domain of the corresponding heavy chains to 
the NH2 terminus of/~2m (10, 11). These single chain MHC 
class I molecules are soluble in the absence of detergent (12). 
The  single chain K d molecule has been more extensively 
studied and found to bind the same repertoire of peptides 
as its native cell surface-expressed counterpart (13), to be func- 
tional, and has provided useful tools to study T  cell activa- 
tion (14). The tridimensional structure of several MHC class 
1  Abbreviations used in this  paper: ~2m, Bz-microglobulin;  ER, endoplasmic 
reticulum; NP, nucleoprotein; SC-K  a, single-chain  K  a molecule. 
493  J. Exp. Med. ￿9  The Rockefeller  University  Press ￿9 0022-1007/95/02/0493/10 $2.00 
Volume 181  February  1995  493-502 I-peptide complexes has been determined by crystallography 
(15-20). The peptide lies in a groove made of a platform of 
3  sheets and two c~ helices encoded by the second and third 
exons of the gene encoding the heavy chain. The overall to- 
pology of these different complexes is similar,  most of the 
interaction resulting from conserved contacts between the 
residues of the MHC groove and conserved structures of the 
peptide. 
In this study, we used this information to genetically con- 
nect an antigenic peptide to the heavy chain of the mouse 
K d molecule. The purpose was to produce cell lines in which 
the density of the chosen MHC-peptide complex would be 
considerably increased. The expectation was that such cells 
would be potent immunogens capable of inducing specific 
CTL from naive mice. We show here that this is the case 
for three  Ka-peptide  fusions  and  that  the  corresponding 
transfected cells are recognized by all specific CTL tested and 
are highly immunogenic in vitro and in vivo. Mice vacci- 
nated with these cells are specifically protected against a sub- 
sequent virus or tumor challenge. In addition, a soluble pep- 
tide-Ka-32m  fusion  was  also  constructed  and  shown  to 
activate in vitro a specific T  cell hybridoma. Thus, the ex- 
tracellular part of MHC molecules can be manipulated at both 
ends.  Such single-chain MHC-peptide complexes could be 
useful in vivo, especially when the native complex has a rapid 
dissociation rate. 
Materials and Methods 
Cell  Lines.  L  (CCL1.3;  American  Type Culture Collection 
[ATCC], Rockville, MD), LK  d, and P815-Cw3 have been previ- 
ously described (21) and were grown in DME supplemented with 
10% FCS. CHO cells or CHO cell transfectants were grown in 
c~-MEM supplemented  with 10% FCS or only 2% for soluble  MHC 
production. 
Plasmid Construction and Transfection.  Unique XhoI and Sinai 
sites were introduced by site directed mutagenesis into the K  d se- 
quence at the ApaI site located at the 3' end of the leader sequence. 
Double strand oligonucleotides encoding the various antigenic pep- 
tides were cloned between these two sites (see Fig. 2). The resulting 
constructs were transfected into mouse L cells (ATCC CCL 1.3). 
Stable transfectants expressing high levels of the fusion proteins 
were selected by flow cytometry sorting by use of the SF1-1.1.1 
mAb (ATCC HB159) in a FACStar  |  station (Becton Dickinson 
& Co., Mountain  View, CA). 
Soluble single-chain Kd-Cw3-N10 was obtained by replacing 
the 5' moiety (a NotI-EcoRV fragment) of the soluble single-chain 
K  d (10) with that from the membrane-bound Ka-Cw3-N10. The 
resulting construct was inserted into pFRSV (22) and transfected 
into CHO cells. Stable transfectants were selected and cultivated 
in increased concentrations of methotrexate as described (22). Cul- 
ture supernatants were tested for K d or peptide-K  d secretion by 
immunoassay. 
Immunoassay for Soluble K s.  96-well plates (CML-Microtest 
Luxlon, Nemours, France) were coated for 2 h with SF1-1.1.1 (anti- 
c~3) at 5/zg/ml in 100 mM carbonate buffer, pH 9.5. After washing 
and blocking with PBS containing 0.5% gelatin, serial dilutions 
of culture supernatants were added to the wells and incubated for 
I h. After washing with PBS, 50/A of 1/xg/ml biotinylated 20-8- 
4S (anti-c~l-~2) (23) was added. Immune complexes were revealed 
with  horseradish peroxidase-conjugated  streptavidin by use of 
o-phenylenediamine  dihydrochloride  (#P8806; Sigma Chemical Co., 
St. Louis, MO) as substrate. 
Immunoprecipitation.  Cells  (10 6) were metabolically  labeled with 
[3SS]methionine (10/~Ci) for 1 h, washed, lysed, and immunopre- 
cipitated as previously  described (13). Immunoprecipitates  were ana- 
lyzed by SDS-PAGE and revealed by fluorography. 
Peptide Elution.  Cells  (109) were lysed and the K  a fusions im- 
munoprecipitated as described (13) with the SF1-1.1.1 mAb. Bound 
peptides were extracted by boiling the immunoprecipitates in 10% 
acetic acid for 10 rain and purified by ultrafiltration  (Centricon 
10; Amicon Corp.,  Danvers, MA). 
CTL Clones and Cytolytic Assays.  The CTL clones used in this 
study were previously described (24-28), and the cytolytic assays 
were performed as described (26). 
T Cell Hybridoma.  The T cell hybridoma 9.4 (14), product of 
the fusion of the Cw3/1.1  CTL clone with the 58 TCR-c~-B- 
hybridoma (29), has been previously described. T cell response was 
determined by measuring IL-2 secretion monitored by its capacity 
to sustain the proliferation of the IL-2-dependent cell line CTLL-2. 
Primary CTL Induction.  Murine nucleoprotein (NP) and Cw3 
primary specific CTL were generated in 5-d MLC by incubating 
3  x  107 splenocytes with 5  x  105 irradiated (10,000 rad) trans- 
fected L cells. Lymphocytes were harvested on day 5 and assayed 
for cytolytic activity on 51Cr-labeled target cells. 
Cytotoxicity Assays.  Cell-mediated cytolytic activities were de- 
tected in a 6oh 51Cr assay. Percent specific  lysis of 104 51Cr-labeled 
target cells in 200/zl was determined for various lymphocyte-to- 
Table 1.  Peptide-K a Fusions Used in  this Study 
Construct  Peptide  Spacer  Cells 
K a  LK  a 
Ka-A21170"185]  RYLENGKETLQRTDAP  GG  L-Kd-A2.1,  -A2.2, -A2.3 
Ka-Cw31170-185]  RYLKNGKETLQRAEHP  GG  L_Kd_Cw31170_185] 
Ka-Cw3-N10  RYLKNGKETL  GGPGGGSGGG  L-Ka-Cw3,  LKa-Cw3_B7 
Kd-Cw3-N20  RYLKNGKETL  GGP(GGGGS)2GGGSGGG  L-Ka-Cw3-N20 
Ka-Cw3-N30  RYLKNGKET  L  GGP(GGGGS)4GGGSGGG  L-Ka-Cw3-N30 
Ka-Cw3-32m  RYLKNGKETL  GGPGGGSGGG  Secreted by CHO 
Ka-NP  TYQRTRALV  GGPGGGSGGG  L-Ka-NP-B7 
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6 and 15% of total incorporated label. The number of cytotoxic 
cells generated by coculture was quantitated in terms of lytic units 
(30). 
Tumor Challenge.  P815-Cw3  tumors were induced in syngeneic 
F~ mice (C3H-OH  x  C3H) by s.c. injection  of 7  x  106 cells 
above the right shoulder blade. Tumor growth was determined by 
measuring tumor dimension at regular time intervals. 
Limiting Dilution Analysis.  Microcultures were initiated under 
limiting dilution analysis conditions in 24-weU replicates, as previ- 
ously described (31). Each microculture  received 10  s irradiated 
splenocytes as feeder cells in 200 pl  RPMI  1640 medium  sup- 
plemented with 10% FCS, 50 U of IL-2, and 5 #g/ml of con A. 
On day 10, each well was split and assayed for cytotoxicity on 
SlCr-labeled P815-Cw3 and P815 target cells in parallel in a 6-h 
SXCr release assay. Individual microcuhures were considered posi- 
tive when SlCr release exceeded three standard deviations of the 
spontaneous release. CTL precursor frequencies were estimated by 
Poisson distribution  analysis. 
Vaccination  Mice  were inoculated three times intraperitoneally 
with 107 transfected L cells at 7-d intervals. 10 d after the last in- 
jection,  mice were challenged with three LDs0 doses of influenza 
virus A/PR/8 in a nasal inoculum. 
Results 
Construction and Cell Surface Expression of H-2K  d Molecules 
with Covalently Bound Peptides.  Oligonucleotides coding for 
different antigenic peptides were inserted into the K a cDNA 
sequence (32) between the signal sequence and the o~1 do- 
main (Figs.  1 and 2). At the 3' junction, a spacer encoding 
a peptidic link made of small side chain residues was added. 
As  listed in  Table  1,  four different Kd-restricted antigenic 
peptides were used: A21170-185] derived from HLA-A2 (25), 
Cw31170-185]  and the optimal 10-mer Cw31170-179],  both 
derived from HLA-Cw3 (33), and NP[147-155]  derived from 
the nucleoprotein of the influenza virus (34). The spacer be- 
tween the antigenic peptide and the NH2-terminal end of 
the oll  domain of K a was  composed of two Gly residues 
for the  16-mers,  A21170-185]  and  Cw31170-185].  For the 
Cw3 10-mer, three spacers were compared: a 10-,  20-, and 
a 30-residue spacer based on the Gly-Gly-Gly-Gly-Ser  motif 
that we and others (10, 35, 36) previously used to produce 
single chain MHC molecules or immunoglobulins.  In the 
construct with NP,  the  10-residue spacer was  used. 
The constructs were transfected into mouse L cells,  and 
stable transfectants were selected.  Using flow cytometry and 
the SF1-1.1.1 anti-K  a mAb,  we determined if the different 
fusion proteins were expressed at the cell surface. As shown 
in Fig.  3 A  for the Ka-A21170-185]  fusion, transfected cells 
expressed high levels of the fusion at their surface.  Similar 
results were found for the other fusions. The same conclu- 
sion was drawn by use of a different anti-K  d mAb, 34-1-2. 
This suggests that the overall structure of the K d portion 
was not altered, as two antibodies specific for two different 
epitopes could recognize the fusion proteins. 
Some fusion proteins have been reported to be cleaved 
when expressed in vivo. We wanted therefore to determine 
if the peptidic part of the fusion was expressed. We did this 
experiment for the Kd-A21170-185] fusion. Since we had no 
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Kd-A2[170-185] 
Kd-Cw3[170-185] 
Kd-cw3.N10 
Kd-Cw3-N20 
Kd-cw3.N30 
Kd-Np 
Kd-Cw3-~2m 
(z2  ~o~1 
(;(3  (,,~0 ~2m  CO 
Figure  1.  Fusion  proteins. (left)  MHC dass I molecules  are heterotrimers 
made of a transmembrane heavy  chain noncovalently  associated to 3zm 
and an antigenic peptide. (middle) Three antigenic peptides (A2, Cw3, 
or NP) were genetically  connected  to the NH2 terminus of the mature 
K  d protein. (right) To produce a single-chain soluble K  d with covalently 
bound peptide, the COOH-terminal  end of  the ol3 domain  was connected 
to the NH2 terminus of 3zm. 
antibody specific for this peptide, we metabolically labeled 
L-Ka-A2.3 cells and immunoprecipitated the cell extract by 
use of the SF1-1.1.1 antibody. After electrophoresis, a single 
band was observed at an apparent molecular mass of 40 kD 
(Fig. 4). Comparison with an immunoprecipitate from L cells 
transfected with the wild-type K d (LK  d) showed a molec- 
ular mass  increase of ,o2 kD,  consistent with the addition 
of 18 amino acids. This indicates that the antigenic peptide 
A2[170-185]  was not cleaved from the fusion protein. Taken 
together, these data indicate that  the fusions between the 
different antigenic peptides and the K d molecule were ex- 
pressed at  the cell surface of the transfected cells. 
Production and Purification of Soluble K d Molecules with Cova- 
lently Bound Antigenic Peptide and fl2m.  We have previously 
described the  construction of a  single-chain  K a molecule 
(SC-K  d) with covalently attached 32m. It was produced by 
Xhol 
ATG GCA s  TGC ACG CTG CTC CTG CTG TTG GCG  GCC GCC CTG GCC CCC ACT CAG A~-~CG 
M  A  P  C  T  L  L  L  L  L  A  A  A  L  A  P  T  Q  T  R  A 
[  signal sequence  I 
Xmal 
CGT TAT TTG AAA AAC GGT AAA fiAA ACT TTG GGT G(~C-'~  GGT GGT TCT GGG GGT GGG 
R  Y  L  K  N  G  K  E  T  L  I  G  G  P  G  G  G  S  G  G  G 
I--  antigenic peptide  I  linker  --J 
GGC CCA CAT TCG CTG AGG TAT TTC GTC ACC GCC GTG TCC CGG CCC GGC CTC GGG GAG  .., 
G  P  H  S  L  R  Y  F  V  T  A  V  S  R  P  G  L  G  E 
I__  mature K d protein 
Figure  2.  Nucleotide  and amino acid sequences  of Kd-Cw3-N10. The 
antigenic peptide (Cw31170-179]) and the peptidic linker were inserted 
between the signal sequence  and the NH2 terminus of the mature K  a pro- 
tein, as explained  in Materials and Methods. The unique XhoI and XmaI 
restriction sites allow the insertion  of different  antigenic  peptides  and linkers. 
Only the 5' and the NH2-terminal  parts of the sequences  are shown. The 
single letter code  is used for amino adds. These  sequence  data are available 
from EMBL/GenBank/DDBJ  under accession  number  X83501, M. mus- 
culus BDH-Cw3 gene. A  B 
350 
..Q 
E 
t- 
m 
o 
....  L 
........  A2.1 
f~  A2.2 
II  A2.3 
I  I  :  \ 
........  i  ........  i  ........  i  ........  i 
Fluorescence  intensity 
40. 
03 
8 
0. 
.01 
AZZ  ,C /  j 
_  ~  N A2.3  /~"~.'""~).a 
........  i  .......  il  ........  i  ....... 
.1  10  100 
E:T 
Figure 3.  Cell  surface  expression  of Ka-Cw3 
[170-185] parallels  recognition  by a specific  CTL 
clone. L cells were transfected  with the Kd-A2 
[170-185] construct.  Three  independent  transfec- 
tants were  analyzed  by flow  cytometry  using  the 
anti-K  d SF1-1.1.1 mAb (A) or for lysis by the 
332/2A CTL clone  specific  for the A2 peptide 
presented by K  a (B). 
connecting the COOH  terminus of the or3 domain of K a 
to the NH2 terminus of 32m (10). This fusion was shown 
to specifically bind peptides (12), select the same repertoire 
of peptides as the native K a molecule (13), and specifically 
interact with its cognate TCR (14). 
We therefore produced a soluble form of one of the pep- 
tide--K  a fusion proteins,  Ka-Cw3-N10. For this purpose,  the 
COOH-terminal end of the or3  domain of Ka-Cw3-N10 
was  connected  to  the  NH2-terminal end of 32m  (Fig.  1, 
right) through a 15-residue spacer. This construct was trans- 
fected into CHO cells with a modified DHFR used as marker. 
Transfected clones were selected and cultivated with increasing 
concentrations of methotrexate. One clone resistant to 1 mM 
methotrexate was selected and subcloned. The culture medium 
of the subclone was tested for the presence of the fusion pro- 
tein by immunoassay, as described in Materials and Methods. 
Between 1 and 3 mg/liter was detected in a 2- to 3-d culture 
supernatant. The peptide--K a protein was purified from cul- 
ture supernatant by immunoaffinity as previously described 
for  SC-K  a.  Thus,  it  is  possible  to  produce  single-chain 
MHC-peptide complex in which all components of the nat- 
Figure  4.  Immunoprecipita- 
tion of the Ka-A2[170-185] fu- 
sion  protein. L cells  expressing  the 
native K  a or the Ka-A21170-185] 
fusion  protein  were  metabolically 
radiolabeled. After lysis, the ex- 
tract was immunoprecipitated  with 
the anti-K  a SF1-1.1.1 mAb and 
analyzed  by gel electrophoresis  on 
a 12% SDS-polyacrylamide  gel. 
Immunoprecipitation products 
were revealed  by fluorography. 
ural  heterotrimer,  that  is,  the heavy chain,  32m,  and the 
peptide, have been fused through appropriate peptidic spacers. 
Recognition of the Cell Surface-expressed Peptide-K  d Fusion 
Proteins by Peptide-specific  Kd-restricted  CTL Clones.  To deter- 
mine if the peptide fusions displayed a structure similar  to 
that of the corresponding Ka-peptide complexes,  we tested 
the recognition of L cells expressing  the Ka-A2[170-185]  or 
Ka-Cw3[170-185]  fusions by CTL clones specific for the A2 
or Cw3 peptides and restricted by K a. Three independent 
transfectants expressing different level of the Ka-A2[170-185] 
fusion were tested for specific recognition by an A2-specific 
Ka-restricted CTL clone (332/2A).  As shown in Fig.  3 B, 
all three transfectants were lysed in the absence of added pep- 
tide, while L cells expressing  the native K a were not lysed. 
Furthermore, the level of lysis paralleled the level of cell sur- 
face expression of the fusion protein (compare Fig. 3, A and B). 
A panel of seven additional independent CTL clones was 
then tested with one of the transfected L cell clones (Fig. 
5). A specific lysis was observed in all cases. For most CTL 
clones,  the percentage of lysis was >80%  at an E/T ratio 
of 10:1. Similarly,  two independent CTL clones specific for 
Cw3  and  restricted by K a lysed  L-Ka-Cw3[170-185]  cells 
(Fig 5). In summary, all nine CTL clones tested recognized 
the  fusion proteins  in  a  way similar  to  the  K a molecule 
loaded with the corresponding peptide. This recognition was 
dose dependent. 
Optimization of the Spacer Length.  Four different fusions 
had been  constructed with the Cw3  peptide  (Fig.  1 and 
Materials and Methods).  Three of them used the optimal 
Cw31170-179] and different spacers of 10, 20, and 30 residues. 
We wanted to compare the CTL recognition of these different 
fusions with that of LK  a cells loaded with exogenous Cw3 
peptide. 
We chose transfectant clones that expressed similar levels 
of the different fusions as judged by flow cytometry and rec- 
ognition by the SF1-1.1.1 mAb. This mAb was chosen be- 
cause it recognizes an epitope in the ol3 domain (11) and was 
therefore expected  to be less sensitive  to the fused peptide 
or spacer. Fig.  6 shows the lysis of these different cells by 
the CTL clone CAS20.  All cells were efficiently recognized 
and only small differences could be noted. While LK  a loaded 
with the Cw3 peptide and L-Ka-Cw31170-185] cells were 
lysed with similar efficiency, the best recognized construct 
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Figure 5.  Recognition of Kd-A21170-185] and Kd-Cw31170-185] by specific CTL clones. A panel of Kd-restricted CTL clones specific for the A2 
peptide (A24/10.1, A24/12.2,  A24/PEFI, A24/PEF2, A24/PEF4, A24/PEF8),  the Cw3 peptide (CASt),  or both peptides (CAS20) was assayed 
for lysis of DK  d cells (open circles), L-Kd-A2.3 (filled circles), or L-Kd-Cw31170-185] (filled triangles). 
was  Kd-Cw3-N10.  Recognition  of  Kd-Cw3-N20  was 
slightly better than that of Kd-Cw31170-185],  while recog- 
nition of Kd-Cw3-N30 was slightly less e~cient. This sug- 
gested that the optimal spacer length was 10 residues; all sub- 
sequent experiments were performed with the Ka-Cw3-N10 
fusion,  hereafter referred to as Kd-Cw3. 
T  Cell Hybridoma Stimulation by Soluble MHC Molecules 
with Covalently Bound Antigenic Peptide and/82m.  We pre- 
viously showed that a single-chain K d in which the heavy 
chain had been connected to B2m could be loaded with ex- 
ogenous peptides,  and that  the resulting complexes could 
specifically interact with their cognate TCR (14). Since L 
cells expressing the different peptide-K  d fusions could be 
recognized by specific CTL, we anticipated that the soluble 
Ka-Cw3-B2m  could  specifically  trigger  a  Ka-restricted 
Cw3-specific T  cell hybridoma. 
T  cells were incubated for 24 h with purified Ka-Cw3 - 
~2m and SF1-1.1.1 mAb in half stoichiometric amount. Cul- 
ture supernatant was tested for IL-2 content by its capacity 
to sustain IL-2-dependent CTLL proliferation. As shown in 
Table 2,  Kd-Cw3-/~2m but not SC-K  a induced IL-2 secre- 
tion by the 9.4 T  cell hybridoma. Antibody alone had no 
effect. We concluded that a heterotrimer made of the MHC 
heavy chain, /32m, and the antigenic peptide can therefore 
be mimicked by a single-chain triple fusion (all in one). 
No Cw3 Peptide Can Be Eluted from  Cells Expressing the 
Kd-Cw3 Fusion Protein.  A small number of MHC-peptide 
complexes presented at the cell surface is su~cient to trigger 
activated T cells (6). Although we could not detect cleaved 
fusion protein after metabolic labeling and immunoprecipi- 
ration (Fig.  4), one could argue that CTL clones lysing the 
L-Kd-Cw3 cells were not recognizing the uncleaved fusion 
protein but rather a peptide derived from the fusion protein 
and presented by the cleaved fusion protein (i.e., Kd). Minute 
quantities of dewed fusion protein could be sufficient for CTL 
triggering but still  undetectable biochemically. 
To rule out this hypothesis, we extracted the peptides from 
L-Ka-Cw3 cells and showed that this peptide mixture did 
not contain the antigenic Cw3 peptide. One billion L-K  a- 
Cw3 cells were lysed and their extract immunoprecipitated 
by use of the anti-K  a SF1-1.1.1 antibody. After acid extrac- 
tion of the immunoprecipitate, peptides were purified and 
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Figure  6.  Optimization  of the spacer length. L cells 
expressing the  same level of K  a,  Kd-Cw31170-185], 
Kd-Cw3-N10,  Kd-Cw3-N20,  or  Kd-Cw3-N30  were 
compared for lysis by the CAS20 CTL clone. 
concentrated  by ultrafiltration  and loaded on P815  cells.  In 
parallel,  peptides were extracted from the  same number of 
P815 cells transfected by the HLA-Cw3  gene (hereafter re- 
ferred as P815-Cw3)  known to present the Cw3 peptide in 
the context  of K a.  As shown  in Table 3,  peptide extracted 
from L-Ka-Cw3 cells did not  sensitize P815  to lysis by the 
CAS20 CTL clone, while peptides extracted from P815-Cw3 
did.  This  demonstrates  that  the  antigenic  peptide  is  not 
presented by LoKd-Cw3  cells and,  therefore,  that  the CTL 
clone CAS20  recognizes  the  uncleaved  fusion protein. 
Coculture of Naive Splenocytes with LKd-Cw3 Cells Allows 
the Generation of Primary Specific CTL.  Cells  expressing  a 
high number of a unique  MHC-peptide  complex on their 
surface have been shown to activate specific CTL in vitro (37). 
As L-Kd-Cw3 cells express a high level of fusion protein at 
their surface, and this fusion mimicks the authentic Ka-Cw3 
complex,  we tested the capacity of these cells to induce  in 
vitro-specific  CTL.  However,  when  L-Kd-Cw3  cells were 
cocultivated with naive splenocytes from C3H-OH  x  C3H 
origin, few lytic units were recovered (Fig. 7). We next trans- 
fected  bKa-Cw3  cells  with  a  cDNA  encoding  the  B7.1 
costimulator  molecule.  As  shown  in  Fig.  7,  these cells  (L- 
Kd-Cw3-B7)  could  now  elicit  primary  CTL  in  vitro.  In 
contrast,  LK  a cells expressing B7-1 and loaded with exoge- 
nous Cw3 peptide were not able to activate specific CTL in 
primary cultures. 
Table 2.  Soluble Kd-Cw3-fl2m Stimulates a T  Cell Hybridoma 
T  cell  response 
Added  antigen  (cpm  x  I0 -s) 
SF1-1.1.1 
SF1,1.1.1  +  SC-K  d 
SF1-1.1.1  +  Ka-Cw3-3~m 
3.5  -+ 0.8 
4.1  _+  0.4 
74.75  _+  2.85 
We next  extended  this  observation to L  cells expressing 
K a fused to a viral peptide (bKd-NP-B7).  As found for the 
Kd-Cw3  fusion,  L  cells expressing both  Kd-NP  and  B7.1 
were able to initiate the activation of naive CTL, while LK  d 
cells expressing B7.1 and loaded with exogenous NP peptide 
had  no  effect.  These  results  indicate  that  ceils  expressing 
different Kd-peptide fusions and the B7.1 molecule acquire 
the ability to specifically activate T  cells in vitro;  both the 
B7.1  molecule  and  the  fusion  protein  play crucial  roles  in 
this process.  Neither  alone is sufficient  to activate primary 
CTL in  vitro. 
In Vivo Priming of Naive Mice with Cells Expressing the K d 
Protein Fusion.  To assess if cells expressing  an MHC  class 
I molecule with a single covalently bound peptide were able 
to prime and protect mice against a subsequent tumoral chal- 
lenge or an acute viral infection, we injected Ft mice (C3H- 
OH  x  C3H) intraperitoneally with L cells expressing B7.1 
and the Kd-Cw3 or the Ka-NP fusions. We compared their 
ability  to  elicit  specific cytolytic activity in vivo. 
As  shown  in  Fig.  8,  mice injected  with  L-Ka-Cw3-B7 
were able to reject a lethal dose of P815-Cw3 in <13 d, while 
mice preimmunized with either the irradiated tumor P815- 
Cw3  or  bKd-Cw3  rejected  the  tumor  in  20  and  25  d, 
Table 3.  Absence of Antigenic Peptide in Extract 
from L-Kd-Cw3 Cells 
Cell extract  Specific lysis 
None  5.4  _+  2.1 
P815-Cw3  27.6  +  2.2 
P815  1.9  _+  1.7 
L-Kd-Cw3  2.5  _+  3.3 
3 #g of soluble Kd-Cw3-32m or soluble SC-K  d were dimerized by use 
of a half stoichiometric amount of SF1-1.1.1 mAb and incubated for 24 h 
with 10  s 9.4 cells. Culture  supernatants were collected and IL-2 secre- 
tion was measured by their capacity to sustain CTLL-2 proliferation. T 
cell response is expressed as [3H]thymidine incorporation by CTLL-2 
cells. Results are means of triplicates  _+  SD. 
P815, P815-Cw3, and L-Kd-Cw3 cells (10  9) were lysed and cell extracts 
were immunoprecipitated by use of the anti-K  d SF1-1.1.1 mAb. Peptides 
were acid extracted from the immunoprecipitates, and presence of the 
Cw3 peptide was assayed by measuring P815 cell lysis by the CAS20 
CTL clone in the presence of peptide extract at an E/T cell ratio of 3. 
Results shown are means of triplicates  +  SD. 
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Figure  7.  Generation  of primary  CTL. 
Primary CTL were generated as described in 
Materials and Methods by coculture of naive 
splenocytes  from  C3H-OH  x  C3H  mice 
with the indicated stimulator cells. Cultures 
were  assayed  for  CTL  activity  on  51Cr- 
labeled P815-Cw3 (left) or P815 in the pres- 
ence of 20/zM NP peptide (right). The results 
of a typical experiment are expressed in lytic 
units. 
respectively.  Mice  injected  with  L  cells  or  LK a cells  ex- 
pressing B7.1 and loaded with exogenous Cw3 peptide were 
not able to reject the P815-Cw3 tumor cells and died within 
25 d after the tumor challenge.  Therefore, exogenous pep- 
tide loading is not sufficient to induce protection,  even in 
the presence of B7.1. 
To test whether L-Kd-Cw3-B7 injection elicits  the induc- 
tion of specific  CTL in vivo, limiting dilution analysis was 
performed 10 d after the injection.  A higher frequency (1/600) 
of Cw3-specific CTL precursors was found in mice immunized 
with L-Ka-Cw3-B7  compared with control mice injected 
with  L-Kd-NP-B7  (<(10 -4)  (data  not  shown).  Mice  im- 
munized with L-Ka-Cw3 cells that did not express B7.1 had 
an intermediate frequency of CTLp (1/2,000),  in agreement 
with the observed delayed rejection of the tumor. We there- 
fore concluded that immunization  of syngeneic mice with 
L cells expressing B7.1  and K a covalently attached  to Cw3 
induced  specific  CTL  and protected  against  the tumor. 
We next extended this observation  to the immune response 
against  influenza virus.  Mice (C3H-OH  x  C3H) received 
three  i.p.  injections  of L-Kd-NP-B7  and  were  then  chal- 
L 
L-Kd-Cw3 
￿9  L-Kd-Cw3-B7 
irradiated  P815-Cw3 
4-  ~  L-Kd-B7  loaded  with  Cw3 
~  3 
1"4 
~  2 
e~ 
0 
F--  1 
0  i  ,  i 
10  20  30 
DAY  POST  CHALLENGE 
Figure  8.  Inhibition of P815-Cw3 tumor growth in mice injected with 
bKd-Cw3.  C3H-OH  x  C3H mice were injected with the indicated ceils. 
After 7  d,  mice were challenged  with  a lethal dose of the tumor  P815- 
Cw3. Tumor size is expressed as the mean diameter of all animals in each 
group  of five.  Mice with  tumors  >4  cm  in diameter  were  killed. 
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lenged with 3 LDs0 of influenza virus A/PR/8  by nasal in- 
jection.  As shown in Fig.  9,  all immunized  mice survived 
without any symptom of disease for >14 d, while all control 
mice injected with L-Kd-Cw3-B7 died within 7 d. This ob- 
servation  suggests that immunization with cells expressing 
MHC class I molecules with covalently bound peptide is of 
general  interest. 
Discussion 
In this study we have constructed several fusion proteins 
in which we connected a Kd-restricted  peptide (Cw3,  A2, 
or NP)  to  the mature K d protein.  After transfection of L 
cells,  these fusion proteins were expressed  at the cell surface 
and recognized by Kd-specific antibodies.  Transfected L cells 
were lysed by all tested Kd-restricted CTL specific  for the 
fused antigenic peptide.  This indicates  that the fusion pro- 
teins display  a structure very similar  to that of the natural 
Ka-peptide  complexes. 
The crystal  structures  of several MHC class  I molecules 
loaded with peptides have been determined (16,  17, 19, 38). 
The topology of the antigenic peptide within  the binding 
site  is  similar  in  all  cases: all  peptides  display  the  same 
NH2-COOH  orientation  in  the deft,  and  the peptide  is 
m 
> 
-'3 
CO 
o~ 
100: 
80 
60 
40- 
20- 
o 
o  2  4  6  8  10  12  14 
Day post challenge 
Figure  9.  Protection against influenza virus acute infection of mice in- 
jected with bKd-NP-B7.  Groups of five C3H-OH  x  C3H mice received 
three  injections  of either  bKd-NP-B7  or  bKd-Cw3-B7  as  indicated. 
After virus  challenge,  mice  were checked  every day for  survival. bound to the class I molecule through mostly conserved in- 
teractions.  The  NH2  terminus  is  deeply buried  into  the 
groove, while the COOH-terminus is more accessible.  As 
a result, addition of a single residue at the NH2 terminus 
of an optimal antigenic peptide is very deleterious to the pep- 
tide-MHC interaction, while addition of few residues at the 
COOH terminus of the peptide is less disturbing for the in- 
teraction (39).  Moreover, relatively long peptides (up to 33 
residues) have been isolated from MHC class I molecules. Pool 
sequencing of these peptides and comparison with the known 
aUelic motifs suggest that some of them may extend out of 
the site on their COOH-terminal end (40, 41). Our finding 
that the COOH-terminal end of the peptide could be ex- 
tended with a peptidic link without altering the overall struc- 
ture of the Kd-peptide complex is compatible with these ob- 
servations. 
The NH2-terminal end of the MHC class I molecule lies 
under the platform made of 3  sheets from the or1 and ot2 
domains and is therefore unlikely to be seen by the TCR. 
Mage et  al.  (42)  produced a  single-chain D d molecule in 
which 32m has been connected to the NH2 terminus of the 
mature heavy chain. Our finding that peptides could be linked 
to the NH2 terminus of the mature K d extends this obser- 
vation. Preliminary modeling of our fusion proteins suggests 
that the linked antigenic peptide lies in the groove of the 
MHC molecule, bulges out at its COOH terminus, and then 
passes under the 3  sheet platform. According to this model, 
the  fusion  protein  would  look  similar  to  the  authentic 
Kd-peptide complex. 
In the different structures of MHC class I molecules de- 
termined by crystallography, the COOH terminus of the pep- 
tide and the NH2 terminus of the or1 domain are spaced by 
about 37 A  . This distance could theoretically be spanned 
by an 11-residue connecting peptide. In agreement with this 
prediction, we found that the best spacer length was 10 amino 
acids. It should be noted, however, that other spacers (20 and 
30 residues) were also efficiently recognized, suggesting that 
the fusion protein can accommodate different spacer lengths. 
This is reminiscent of what we previously found when we 
used the same type of spacers to connect the ectodomain of 
K a to 32m. As long as the spacer was/>5 amino acids long, 
the fusions were correctly folded (10). 
While this work was in progress, Kozono et al. (43) fused 
antigenic peptides to the 3 chain of soluble MHC class II-mol- 
ecules. They showed that such MHC class II-peptide fusions 
are recognized by specific T  cells.  While the peptide cleft 
of MHC class I is more narrow at each end, our results show 
the feasibility of this approach for class I. Therefore, for both 
class I and class II, it is possible to produce molecules pre- 
senting a single peptide. 
We also produced a soluble form of the Ka-Cw3 fusion 
by connecting the COOH-terminal end of the or3 domain 
of the Ka-Cw3 fusion to the NH2 terminus of 32m. This 
triple fusion was capable of triggering a specific T  cell hy- 
bridoma. The extracellular part of MHC class I molecules 
can therefore be manipulated at both ends simultaneously. 
There is a potential advantage in using peptide-MHC  fu- 
sions over peptide-MHC complexes. Peptide-MHC complexes 
are quite stable  at 4~  or at room temperature. However, 
some dissociate rapidly at 37~  Their half life in injected 
animals is therefore expected to be short. Having the peptide 
covalently bound to the MHC molecules should stabilize these 
labile complexes and increase their biological effects. 
Two lines of evidence suggest that CTL recognized the 
undeaved fusion protein. First, when L cells transfected with 
the Ka-A21170-185] fusion were radiolabeled and the fusion 
protein precipitated with an anti-K  a antibody, a single band 
at the expected molecular weight was observed after elec- 
trophoresis and autoradiography. No degradation product 
was detected. Second, when we extracted the peptides from 
L-Kd-Cw3 cells, we could not detect any Cw3 peptide using 
a CTL clone as a readout. This is somehow surprising since 
the fusion protein is an endogenous protein and should be 
processed following the MHC class I pathway. Thus, the Cw3 
peptide either is not produced by the processing machinery 
or is not translocated by the ~p gene products into the ER; 
alternatively, it is produced and degraded, presumably be- 
cause it does not bind any class I molecule within the ER 
(44). However, when it is attached to K a, it is protected and 
therefore presented at the cell surface. 
Cells  expressing peptide-K  a fusions  were found  to  be 
highly immunogenic in two experimental systems involving 
the P815-Cw3 tumor and the influenza virus. The immunoge- 
nicity was tested in vitro by measuring the generation of pri- 
mary CTL and in vivo by testing the protection against a 
lethal  challenge  and  measuring  the  frequency  of  CTL 
precursors.  In these experiments, cells expressing the pep- 
tide-K  a fusions were compared with ceils expressing K d and 
loaded with exogenous peptides. Exogenous peptide loading 
was found incapable of inducing CTL in vitro or in vivo. 
In vitro, but not in vivo,  the B7.1  molecule was required 
for CTL induction. However, in vivo, a more rapid rejection 
of the tumor and a higher frequency of CTL precursors was 
found when the cells expressed both the B7.1 and fusion mol- 
ecules. 
Several hypotheses could account for the increased im- 
munogenicity of cells expressing the peptide-MHC fusions 
over cells loaded with exogenous peptides:  (a) cells expressing 
the peptide-MHC fusions express a higher number of specific 
MHC-peptide complexes per cell. As already mentioned, the 
number  of MHC-peptide  complexes per  cell  required is 
different for the recognition by an already activated CTL and 
for the induction of naive T  cells.  High numbers of pep- 
tide-MHC complexes per cell, which can be achieved by use 
of different strategies,  including acid treatment (45) or use 
of tap gene mutants (46, 47), results in primary CTL induc- 
tion. (b) The peptide-MHC fusions are more stable than nat- 
ural peptide-MHC complexes. This explanation applies par- 
ticularly for in vivo experiments where natural MHC-peptide 
complexes are susceptible to dissociation. In these situations, 
peptide-MHC fusions open new possibilities.  (c) The pep- 
tide-MHC fusions are continually renewed. This is not the 
case when animals are injected with cells loaded with exoge- 
nous peptides. Experiments using minigenes to drive the ex- 
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tion of new complexes is an important parameter of in vivo 
immunogenicity.  (d)  In  cells  transfected  with  the  pep- 
tide-K  a fusions, K a is exclusively or preferentially  associated 
with the fused peptide.  No cleavage product of the fusion 
could be detected, but it remains possible that a number of 
peptides still bind in the groove of the fusion protein. Fur- 
thermore, only a fraction of the fused peptide may display 
the immunologically  competent conformation. It should also 
be noted that transfected cells express K k and D k in addi- 
tion to the peptide-K  d fusion protein so that, in any case, 
the fused peptide is not the only one presented by the trans- 
fected cells. If TCR aggregation is important for T cell trig- 
gering, specific MHC-peptide complex density rather than 
number per cell may be an important parameter (47). How- 
ever, as previously noted by De Bruijn et al. {47), a relatively 
small increase in the density of MHC-peptide complexes is 
probably sufficient for the induction of a T cell response. More 
work is needed to discriminate between these different ex- 
planations. 
In conclusion, single-chain MHC-peptide fusions can be 
produced for both class I and class II. These fusions may prove 
useful for manipulating the immune response,  in particular 
when the antigenic peptide has a low affinity for the MHC 
molecule, as may often be the case for tumor-derived anti- 
genic peptides. Thymic injection of cells expressing an MHC 
class I molecule bound to a single antigenic peptide or produc- 
tion of mice transgenic for such fusions would be invaluable 
for studying positive selection  of T  cells. 
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